(Q44384822)

2 December 2017

title

Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues (English)

1 reference

2 December 2017

8

1 reference

2 December 2017

M A Muros

1

1 reference

2 December 2017

M Varsavsky

2

1 reference

2 December 2017

P Iglesias Rozas

3

1 reference

2 December 2017

J Valdivia

4

1 reference

2 December 2017

J R Delgado

5

1 reference

2 December 2017

F Forrer

6

1 reference

2 December 2017

L Bodei

7

1 reference

2 December 2017

language of work or name

1 reference

1 January 2009

1 reference

Clinical and Translational Oncology

2 December 2017

published in

1 reference

2 December 2017

volume

11

1 reference

2 December 2017

issue

1

1 reference

2 December 2017

page(s)

48-53

1 reference

Therapeutic advances of nuclear medicine in oncology

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12094-009-0310-5

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-009-0310-5

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-009-0310-5

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-009-0310-5

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

21 January 2018

1 reference

12 December 2020

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

1 reference

12 December 2020

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

12 December 2020

Candidates for peptide receptor radiotherapy today and in the future.

1 reference

12 December 2020

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

12 December 2020

Neuroendocrine tumours

1 reference

12 December 2020

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

12 December 2020

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

12 December 2020

Inhibition of kidney uptake of radiolabeled somatostatin analogs: amino acids or gelofusine?

1 reference

12 December 2020

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

12 December 2020

Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin.

1 reference

12 December 2020

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

12 December 2020

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

1 reference

12 December 2020

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

1 reference

12 December 2020

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

1 reference

12 December 2020

Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis

1 reference

12 December 2020

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

12 December 2020

10.1007/S12094-009-0310-5

Identifiers

DOI

1 reference

2 December 2017

1 reference